Amgen kicks back I/O drug at center of $500M deal, leaving biotech partner alone to ponder next steps
Just ahead of a planned Phase I readout, Amgen is punting back an immuno-oncology drug to Molecular Partners.
Amgen cited a “strategic pipeline review” for the decision to return rights to MP0310, previously named AMG 506, to the biotech. Like the rest of Molecular Partners’ pipeline, it’s a DARPin — an engineered antibody mimetic protein — but it specifically binds to fibroblast activation protein (FAP) on tumor stromal cells and 4-1BB on T cells.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.